MetaCap

KALA BIO (KALA) vs Purple Biotech (PPBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Purple Biotech is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KALA+651.39%PPBT+4.45%
+1015%+451%-113%
Oct 7, 20261 yearNov 20, 2026
KALA+820.38%PPBT+14.66%
+864%+384%-96%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KALA versus PPBT key metrics
MetricKALAPPBT
Share price$2.71$1.53
Market cap$1.74M$1.86M
1-day change-10.28%-4.09%
EPS (TTM)$-321.30$-47.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-26.98M$-26.39M
52-week high$2,865.00$8.90
52-week low$2.65$0.91
Distance from 52-week high-99.91%-82.87%
Analyst consensus—none
Avg. price target upside—+1014.75%
Average volume52.52K1.26M
Shares outstanding644.66K1.22M
Employees610
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About KALA BIO

KALA stock →

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

KALA vs PPBT FAQ

Which is bigger, KALA BIO or Purple Biotech?

Purple Biotech (PPBT) is larger, with a market capitalization of $1.86M compared with $1.74M for KALA BIO (KALA).

Are KALA BIO and Purple Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons